Log In
Print
BCIQ
Print
Print this Print this
 

Factor IX-albumin fusion protein, rIX-FP (CSL654)

  Manage Alerts
Collapse Summary General Information
Company CSL Ltd.
DescriptionRecombinant fusion protein linking recombinant coagulation Factor IX with recombinant albumin
Molecular Target Factor IX
Mechanism of Action 
Therapeutic ModalityBiologic: Fusion protein
Latest Stage of DevelopmentRegistration
Standard IndicationHemophilia
Indication DetailsTreat and prevent bleeding episodes in hemophilia B patients; Treat hemophilia B
Regulatory Designation U.S. - Orphan Drug (Treat and prevent bleeding episodes in hemophilia B patients);
EU - Orphan Drug (Treat and prevent bleeding episodes in hemophilia B patients);
Switzerland - Orphan Drug (Treat and prevent bleeding episodes in hemophilia B patients)
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today